Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia

NCT00972231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2015-09-01

No results posted yet for this study

Summary

Iron overload impaired growth in Thalassemia patients due to iron deposition in the endocrine glands, including the hypophysis and gonads. The issue of iron overload in Sickle Cell Anemia is recently studied more extensively and preliminary studies shows that endocrine damage is rarer in those patients.

Growth velocity was not systematically studied in patients with Iron Overload, even in thalassemia patients in spite several studies that assess the endocrine function in those patients. In Sickle Cell Patients this issue was not studied.

The purpose of this study is to assess the growth velocity in a cohort of Thalassemia Major and Intermedia patients and compare the results to another group of Sickle Cell patients, including Sickle cell thalassemia.

Conditions

Interventions

OTHER

Medical Chart Summary

Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Ariel Koren, MD · Pediatric Dpt B and Pediatric Hemaology Unit - Ha'Emek Medical Center - Afula - Israel

  • Carina Levin, MD · Pediatric Hematology Unit, Ha'Emek Medical Center, Afula, Israel

  • Daniela Mathov, Student · Pediatic Hematology Unit, Ha'Emek Medical Center, Afula, Israel

Eligibility

Min Age
5 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00972231 on ClinicalTrials.gov